您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > Natalizumab
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Natalizumab
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
CAS NO:189261-10-7
包装与价格:
包装价格(元)
10mg电议
25mg电议
50mg电议
100mg电议

产品名称
那他珠单抗
产品介绍
Natalizumab 是一种重组的人源化 IgG4 单克隆抗体,与 α4β1-整联蛋白 (α4β1-integrin) 结合并阻断其与血管细胞粘附分子 1 (VCAM-1) 的相互作用。Natalizumab 可用于复发缓解型多发性硬化症和克罗恩氏病的研究。Natalizumab 也可阻止淋巴细胞进入中枢神经系统,从而防止急性脱髓鞘复发。
生物活性

Natalizumab is a recombinant, humanizedIgG4monoclonal antibody, binds to α4β1-integrinand blocks its interaction with vascular cell adhesion molecule-1 (VCAM-1). Natalizumab can be used for the treatment of relapsing remitting multiple sclerosis and Crohn's disease. Natalizumab is also the first targeted therapy which blocks an essential mechanism for lymphocyte entry to the CNS and thus prevents acute demyelinating relapses[1].

IC50& Target

α4β1

 

体外研究
(In Vitro)

Natalizumab, a recombinant, humanized antibody, binds to α4β1-integrin and blocks its interaction with VCAM-1. As a result, leukocyte migration into brain tissue is inhibited, reducing inflammation and preventing the formation of lesions. Natalizumab may also inhibit ongoing central nervous system (CNS) inflammation, mediated by leukocytes already present in the CNS, by interrupting the interactions between α4-integrin-expressing leukocytes and extracellular matrix proteins such as fibronectin and osteopontin[1].

体内研究
(In Vivo)

Natalizumab binds rapidly and with high affinity to α4-integrin. Maximal binding (≥80% saturation), measured in vitro on isolated lymphocyte membranes, occurred 24 hours after intravenous (IV) doses of natalizumab 1 mg/kg to 6 mg/kg[1].

Clinical Trial
性状

Liquid

CAS 号

189261-10-7

中文名称

那他珠单抗

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.